HST Global, Inc. Announces Continued Success with Dr. Forsythe’s “FIT” Protocol

Study is Meeting with 70-80% Efficacy in Clinical Treatment of Stage IV Cancers in Test of 450 Patients

HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc., (OTCBB: HSTC) today announced that Dr. James Forsythe, MD, HMD, is experiencing continuous success with his Forsythe Immune Therapy (FIT) Protocol. Dr. James Forsythe, MD, HMD, is a board certified oncologist and a member of HST Global Inc.’s Board of Directors and Scientific Advisory Board.

“We are encouraged by the continued success Dr. Forsythe is experiencing with his FIT protocol. The updated study results demonstrate the efficacy of the FIT Protocol.”

Dr. Forsythe’s existing study is meeting with 70-80% efficacy in clinical treatment of Stage IV cancers in a test of 450 patients. The highlight of the study is in stage IV prostate cancer where they have met with 86% efficacy with prostate cancer patients over 55 months through the application of his “FIT” Protocol.

Ronald Howell President & CEO of HST Global, Inc. stated, "We are encouraged by the continued success Dr. Forsythe is experiencing with his FIT protocol. The updated study results demonstrate the efficacy of the FIT Protocol."

About HST Global, Inc.

HST Global, Inc. is an Integrated Biotechnology Health and Wellness company that is developing and or acquiring a network of Wellness Centers worldwide that are primarily focused on the immunotherapy and alternative treatment of late stage cancer. In addition, the company intends to acquire innovative products for the treatment of late stage cancer. In this regard, the company primarily focuses on immunotherapy and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer.

HST Global, Inc. wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.